New York Genome Center and Sohn Conference Foundation Collaborate on Pediatric Cancer Research
A multi-institutional effort will fight pediatric leukemia and neuroblastoma.
The New York Genome Center (NYGC) and The Sohn Conference Foundation launched The Sohn Collaborative for Pediatric Cancer Research, a multi-institutional effort with the goal of fighting two childhood cancers: pediatric leukemia and neuroblastoma. NYGC will act as a nexus and participant in this research collaborative with five of its Institutional Founding Members: Columbia University, Memorial Sloan Kettering Cancer Center, New York University School of Medicine, The Rockefeller University, and Weill Cornell Medical College. NYGC will also conduct the genome sequencing and computational analysis for this synergistic research endeavor.
The Sohn Conference Foundation’s grant empowers these institutions to harness their collective knowledge and technology to apply genomic science to identify and analyze why some children’s tumors respond readily to treatment, while other patients suffer relapses or have no response at all. While leukemia and neuroblastoma are different-leukemia affects blood and neuroblastoma is the commonest childhood solid tumor-researchers will pursue a similar approach to understand them. Sequencing the genomes of “outlier” tumors, those that have unusual responses to treatment, either good or bad, may yield valuable clues on how to fight these cancers more effectively
Source: The New York Genome Center
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
